Fig. 2

Transplantation of MHC-mismatched mESC-TEPs prevents insulitis and T1D development in the MHC-matched BMT recipients. Wild-type NOD mice were injected i.v. with anti-CD3/CD8 Abs on days − 8 and − 3 as in Fig. 1. On day 0, the conditioned mice were injected i.v. with BM and CD4⁺ T cell-depleted spleen cells (20 × 10⁶ each) from MHC-matched H-2^g7 B6 mice. Groups of the BMT recipient were also injected i.t. with MHC-mismatched B6 mESC-EpCAM1⁺ TEPs (5 × 10⁴) or mESC-EpCAM1⁻ control cells (5 × 10⁴). Diabetes development was monitored weekly by blood glucose analysis. On day 100, the pancreas, spleen, BM, and thymus were harvested from the mice. a Diabetes development curve after BMT. b Representative sections of H&E staining, and statistical analysis of the percentages of insulitis (right bottom). a, b The data are pooled from three independent experiments (4–5 mice per group in each experiment). c One representative FACS profile of spleen cells for the percentages of donor (CD45.2⁺) or host (CD45.2⁻) T cells (TCR⁺) and B cells (B220⁺). d One representative FACS profile of BM cells for the percentages of donor (CD45.2⁺) or host (CD45.2⁻) B cells (B220⁺). e Gated donor (CD45.2⁺) or host (CD45.1⁺) thymocytes were shown in CD4 versus CD8. The percentages of CD4⁺CD8⁺ DP thymocytes are shown